Peptibase
Weight Loss

Orforglipron

Also known as: LY3502970, OWL833

Clinical Trials
Share:

Key Facts: Orforglipron

Category
Weight Loss
FDA Status
Not FDA Approved
Clinical Status
Phase 3 Clinical Trials
Administration
Oral tablet daily
Typical Dose
Limited community data available
Frequency
See research protocols
Evidence Level
Human Trials
Duration
Long-term use expected
Also Known As
LY3502970, OWL833

What to Expect

An oral non-peptide GLP-1 receptor agonist. Could provide injection-free alternative to semaglutide and tirzepatide.

Mechanism of Action

Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide.

Research Summary

Phase 2 trials showed up to 14.7% weight loss at 36 weeks with daily dosing. Comparable efficacy to injectable GLP-1s. Phase 3 trials ongoing for diabetes and obesity.

Clinical Status:Phase 3 Clinical Trials
Trial Progress:Phase III
Pre
I
II
III
IV
FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical Dosingⓘ

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research Dosingⓘ

Scientific studies

Doses from clinical trials

Duration

Long-term use expected

Administration

Oral tablet daily

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Diarrhea (19-26%)
  • ●Nausea (13-18%)
  • ●Vomiting
  • ●GI events mild-moderate
  • ●Pulse increase
  • ●Investigational - not yet approved

References

Related Peptides

Peptides commonly compared with Orforglipron or used in similar applications.

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.

Weight Loss

CagriSema

Clinical Trials

A combination of semaglutide and cagrilintide (amylin analog) in development. Aims to provide superior weight loss through dual mechanisms.

Weight Loss

Survodutide

Clinical Trials

A dual GLP-1/glucagon receptor agonist in development for obesity and NASH. Combines appetite suppression with increased energy expenditure.

Weight Loss

Cagrilintide

Clinical Trials

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

Weight Loss

Semaglutide

FDA

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.

Weight Loss
How to Use OrforglipronOrforglipron AlternativesCompare with SimilarBrowse All Peptides

Want updates on Orforglipron research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Educational Information Only

This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.

Back to all peptides